Catalysts for $NVS
563 tracked
Jun 6, 2022
approval
LEQVIO (INCLISIRAN SODIUM) — FDA approval
inclisiran
→
May 27, 2022
approval
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
May 27, 2022
approval
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Mar 24, 2022
approval
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Mar 23, 2022
approval
PLUVICTO (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN) — FDA approval
lutetium Lu 177 vipivotide tetraxetan
→
Mar 16, 2022
approval
SANDIMMUNE (CYCLOSPORINE) — FDA approval
Restasis
→
Feb 4, 2022
approval
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Jan 28, 2022
approval
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Jan 28, 2022
approval
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Jan 28, 2022
approval
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Dec 22, 2021
approval
LEQVIO (INCLISIRAN SODIUM) — FDA approval
inclisiran
→
Dec 22, 2021
approval
COSENTYX (SECUKINUMAB) — FDA approval
NOVARTIS AG
→
Dec 22, 2021
approval
COSENTYX (SECUKINUMAB) — FDA approval
NOVARTIS AG
→
Dec 3, 2021
approval
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Dec 3, 2021
approval
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Oct 29, 2021
approval
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
Oct 29, 2021
approval
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
May 28, 2021
approval
COSENTYX (SECUKINUMAB) — FDA approval
NOVARTIS AG
→
May 7, 2021
approval
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
May 7, 2021
approval
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Aug 20, 2020
approval
KESIMPTA (OFATUMUMAB) — FDA approval
KESIMPTA
→
Aug 10, 2020
approval
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Aug 10, 2020
approval
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Jun 23, 2020
approval
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Jun 16, 2020
approval
COSENTYX (SECUKINUMAB) — FDA approval
NOVARTIS AG
→
Apr 9, 2020
approval
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Apr 9, 2020
approval
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Jan 29, 2020
approval
COSENTYX (SECUKINUMAB) — FDA approval
NOVARTIS AG
→
Oct 6, 2019
approval
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Oct 6, 2019
approval
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→